Because of this ambiguity with respect to treatment end-point, and the fact that HBeAg-negative patients are
more susceptible to relapse with
one year of therapy cessation, it is recommended that patients undergo long-term therapy of which the optimal duration is unknown. Importantly, relapses are a common occurrence, even in patients who exhibit persistently undetectable serum HBV DNA by PCR assays." I think this means the same with what you have been saying?